Norges Bank Editas Medicine, Inc. Transaction History

Norges Bank

  • $716 Trillion
  • Q3 2024

Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023
SELL
$6.92 - $9.31 $2.54 Million - $3.41 Million
-366,338 Closed
0 $0
Q2 2023

Aug 14, 2024
BUY
$6.36 - $11.47 $1.7 Million - $3.06 Million
266,799 New
266,799 $2.2 Million
Q2 2023

Aug 14, 2023
SELL
$6.36 - $11.47 $2.33 Million - $4.2 Million
-366,338 Closed
0 $0
Q1 2023

May 15, 2024
BUY
$7.03 - $11.53 $1.88 Million - $3.08 Million
266,799 New
266,799 $1.93 Million
Q4 2022

Feb 14, 2023
BUY
$8.32 - $13.21 $3.05 Million - $4.84 Million
366,338 New
366,338 $3.25 Million
Q3 2022

Nov 13, 2023
BUY
$12.16 - $19.42 $4.45 Million - $7.11 Million
366,338 New
366,338 $4.48 Million
Q2 2022

Aug 14, 2023
BUY
$9.99 - $21.35 $3.66 Million - $7.82 Million
366,338 New
366,338 $4.33 Million
Q1 2022

May 12, 2023
BUY
$14.08 - $27.63 $1.75 Million - $3.43 Million
124,289 Added 33.93%
490,627 $9.33 Million
Q1 2022

May 09, 2022
SELL
$14.08 - $27.63 $6.91 Million - $13.6 Million
-490,627 Closed
0 $0
Q4 2021

Mar 09, 2022
BUY
$26.55 - $40.57 $13 Million - $19.9 Million
490,627 New
490,627 $13 Million
Q3 2021

Nov 14, 2022
BUY
$39.27 - $72.94 $17.4 Million - $32.4 Million
443,829 New
443,829 $18.2 Million
Q3 2021

Nov 05, 2021
SELL
$39.27 - $72.94 $16.4 Million - $30.5 Million
-418,547 Closed
0 $0
Q2 2021

Aug 15, 2022
BUY
$31.29 - $56.64 $13.1 Million - $23.7 Million
418,547 New
418,547 $23.7 Million
Q2 2021

Aug 10, 2021
SELL
$31.29 - $56.64 $18.8 Million - $34 Million
-600,729 Closed
0 $0
Q1 2021

May 09, 2022
BUY
$39.71 - $90.58 $23.9 Million - $54.4 Million
600,729 New
600,729 $25.2 Million
Q1 2021

May 07, 2021
SELL
$39.71 - $90.58 $26.7 Million - $60.9 Million
-672,705 Closed
0 $0
Q4 2020

Mar 02, 2021
BUY
$27.07 - $84.35 $18.2 Million - $56.7 Million
672,705 New
672,705 $47.2 Million
Q4 2020

Feb 10, 2021
SELL
$27.07 - $84.35 $16.1 Million - $50.2 Million
-595,458 Closed
0 $0
Q3 2020

Nov 12, 2021
BUY
$28.06 - $37.16 $16.7 Million - $22.1 Million
595,458 New
595,458 $16.7 Million
Q3 2020

Nov 10, 2020
SELL
$28.06 - $37.16 $18.4 Million - $24.4 Million
-656,466 Closed
0 $0
Q2 2020

Aug 13, 2021
BUY
$18.5 - $34.34 $12.1 Million - $22.5 Million
656,466 New
656,466 $19.4 Million
Q2 2020

Aug 07, 2020
SELL
$18.5 - $34.34 $12.4 Million - $23 Million
-671,144 Closed
0 $0
Q1 2020

May 07, 2021
BUY
$14.88 - $32.78 $9.99 Million - $22 Million
671,144 New
671,144 $13.3 Million
Q1 2020

May 08, 2020
SELL
$14.88 - $32.78 $10.2 Million - $22.4 Million
-682,259 Closed
0 $0
Q4 2019

Mar 03, 2020
BUY
$19.49 - $32.63 $13.3 Million - $22.3 Million
682,259 New
682,259 $20.2 Million
Q4 2019

Feb 12, 2020
SELL
$19.49 - $32.63 $13.3 Million - $22.3 Million
-682,259 Closed
0 $0
Q3 2019

Nov 13, 2020
BUY
$22.49 - $26.81 $15.3 Million - $18.3 Million
682,259 New
682,259 $15.5 Million
Q3 2019

Nov 08, 2019
SELL
$22.49 - $26.81 $12.2 Million - $14.6 Million
-543,727 Closed
0 $0
Q2 2019

Aug 13, 2020
BUY
$20.48 - $27.76 $11.1 Million - $15.1 Million
543,727 New
543,727 $13.5 Million
Q2 2019

Aug 09, 2019
SELL
$20.48 - $27.76 $7.67 Million - $10.4 Million
-374,329 Closed
0 $0
Q1 2019

May 11, 2020
BUY
$19.43 - $26.41 $1.28 Million - $1.73 Million
65,664 Added 21.27%
374,329 $9.15 Million
Q4 2018

Mar 04, 2019
BUY
$18.19 - $31.79 $5.61 Million - $9.81 Million
308,665 New
308,665 $7.02 Million
Q4 2018

Feb 08, 2019
SELL
$18.19 - $31.79 $3.69 Million - $6.45 Million
-202,874 Closed
0 $0
Q3 2018

Nov 12, 2019
BUY
$27.65 - $38.39 $5.61 Million - $7.79 Million
202,874 New
202,874 $6.46 Million

Others Institutions Holding EDIT

# of Institutions
248
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email